Efalizumab-induced autoimmune pancytopenia.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 17034539.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Efalizumab is a recombinant, humanized monoclonal anti-CD11a antibody used for the treatment of moderate to severe plaque psoriasis. Immune-mediated thrombocytopenia and anaemia have previously been reported with this therapy. We describe the first case of immune-mediated pancytopenia in a patient treated with efalizumab. Close monitoring of all blood cell counts is warranted in light of this case.
Medical subject headings
- Antibodies, Monoclonal
- Autoimmune Diseases
- Dermatologic Agents
- Pancytopenia
- Psoriasis